Kura Oncology Balance Sheet Health
Financial Health criteria checks 6/6
Kura Oncology has a total shareholder equity of $505.1M and total debt of $9.4M, which brings its debt-to-equity ratio to 1.9%. Its total assets and total liabilities are $553.9M and $48.8M respectively.
Key information
1.9%
Debt to equity ratio
US$9.38m
Debt
| Interest coverage ratio | n/a |
| Cash | US$527.12m |
| Equity | US$505.08m |
| Total liabilities | US$48.82m |
| Total assets | US$553.91m |
Recent financial health updates
Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Recent updates
Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate
Dec 07Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow
Nov 17Financial Position Analysis
Short Term Liabilities: KURA's short term assets ($537.8M) exceed its short term liabilities ($32.3M).
Long Term Liabilities: KURA's short term assets ($537.8M) exceed its long term liabilities ($16.6M).
Debt to Equity History and Analysis
Debt Level: KURA has more cash than its total debt.
Reducing Debt: KURA's debt to equity ratio has reduced from 5% to 1.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KURA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KURA has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 20.3% each year.